Blue Cross Blue Shield - Iowa Coverage Criteria
Latest Blue Cross Blue Shield - Iowa coverage criteria updates25
- Coverage CriteriaClinical/Medical PolicyEff. 2026-08-15Wegovy (semaglutide) — Supplemental Indications (cardiovascular risk reduction and MASH)Defines coverage, prior authorization documentation, prescriber specialty requirements, and medical necessity criteria for Wegovy (semaglutide) injection and tablet when used for cardiovascular risk reduction and metabolic dysfunction-associated steatohepatitis (MASH). Applies to Blue Cross Blue Shield - Iowa members where benefits exist.All Blue Cross Blue Shield - Iowa updates
- Coverage CriteriaClinical/Medical PolicyEff. 2026-08-14Kineret (anakinra) — Coverage CriteriaDefines prior-authorization, documentation, prescriber specialty, and medical necessity criteria for Kineret (anakinra) for FDA-approved and compendial indications for Blue Cross Blue Shield - Iowa members.All Blue Cross Blue Shield - Iowa updates
- Coverage CriteriaClinical/Medical PolicyEff. 2026-08-11Multiple Sclerosis — Disease‑Modifying TherapiesDefines prior authorization, preferred‑drug sequencing, and medical necessity criteria for disease‑modifying therapies for relapsing and other forms of multiple sclerosis for Blue Cross Blue Shield - Iowa members.All Blue Cross Blue Shield - Iowa updates
- Coverage CriteriaClinical/Medical PolicyEff. 2026-08-05Kerendia (finerenone) — Coverage CriteriaThis policy governs prior authorization and medical necessity criteria for coverage of Kerendia (finerenone) for adults with chronic kidney disease and type 2 diabetes or heart failure, per Blue Cross Blue Shield - Iowa.All Blue Cross Blue Shield - Iowa updates
- Coverage CriteriaClinical/Medical PolicyEff. 2026-07-31Enzyme Replacement Therapy (Coverage Criteria)Policy governing prior authorization and coverage criteria for FDA-approved enzyme replacement therapies for specified inherited/metabolic disorders for Blue Cross Blue Shield - Iowa members.All Blue Cross Blue Shield - Iowa updates
- Coverage CriteriaClinical/Medical PolicyEff. 2026-07-29Esbriet (pirfenidone) for idiopathic pulmonary fibrosisDefines prior authorization, documentation, and medical necessity criteria for Esbriet (pirfenidone) use in members with idiopathic pulmonary fibrosis (IPF) for Blue Cross Blue Shield - Iowa.All Blue Cross Blue Shield - Iowa updates
- Coverage CriteriaClinical/Medical PolicyEff. 2026-07-29Increlex (mecasermin) — Coverage Criteria for Severe Primary IGF-1 DeficiencyThis policy governs medical necessity criteria, prior authorization documentation, prescriber requirements, and continuation/initial approval rules for Increlex (mecasermin) in pediatric patients with severe primary IGF-1 deficiency or GH gene deletion with neutralizing antibodies to GH for Blue Cross Blue Shield - Iowa members.All Blue Cross Blue Shield - Iowa updates
- Coverage CriteriaClinical/Medical PolicyEff. 2026-06-11Otezla (apremilast) prior authorization and coverage policyDefines medical necessity criteria, required documentation, prescriber specialty, quantity limits, dosing guidance, continuation criteria, and exclusions for coverage of Otezla (apremilast) for plaque psoriasis, psoriatic arthritis, Behçet's disease oral ulcers, and immune checkpoint inhibitor-related toxicity for Wellmark Blue Cross and Blue Shield.All Blue Cross Blue Shield - Iowa updates
- Coverage CriteriaClinical/Medical PolicyEff. 2026-06-06Colony Stimulating FactorsPolicy governs prior authorization, preferred and targeted colony stimulating factor products, and coverage criteria for Blue Cross Blue Shield - Iowa members requesting CSF therapy.All Blue Cross Blue Shield - Iowa updates
- Coverage CriteriaClinical/Medical PolicyEff. 2026-06-06Colony Stimulating FactorsDefines preferred short- and long-acting colony stimulating factor (CSF) products, exception criteria, documentation and prior authorization requirements for coverage, and clinical criteria for initial and continuation approval for selected products (notably Rolvedon). Affects prescribers and members under Blue Cross Blue Shield - Iowa benefit plans.All Blue Cross Blue Shield - Iowa updates
- Coverage CriteriaClinical/Medical PolicyEff. 2026-06-06Lomitapide (Juxtapid) for homozygous familial hypercholesterolemia — Coverage CriteriaDefines medical necessity, prior authorization requirements, and documentation for Juxtapid (lomitapide) used as adjunct therapy in patients with homozygous familial hypercholesterolemia (HoFH). Applies to Wellmark/Blue Cross Blue Shield members covered under applicable contracts.All Blue Cross Blue Shield - Iowa updates
- Coverage CriteriaClinical/Medical PolicyEff. 2026-06-04Cosentyx (secukinumab) drug policyDefines coverage, prior authorization requirements, documentation, prescriber specialties, and clinical criteria for Cosentyx (subcutaneous and intravenous formulations) for Wellmark/Blue Cross Blue Shield members.All Blue Cross Blue Shield - Iowa updates
- Coverage CriteriaClinical/Medical PolicyEff. 2026-06-04Cosentyx (secukinumab) — Coverage Criteria and Prior AuthorizationDefines coverage, prior authorization requirements, required documentation, and clinical criteria for Cosentyx (subcutaneous and intravenous formulations) for multiple inflammatory dermatologic and rheumatologic indications for Wellmark Blue Cross and Blue Shield members.All Blue Cross Blue Shield - Iowa updates
- Coverage CriteriaClinical/Medical PolicyEff. 2026-06-04Skyrizi (risankizumab-rzaa) coverage and prior authorization policyDefines clinical criteria, documentation, prescriber specialties, approval durations, continuation criteria, TB screening, quantity limits, dosing/admin guidance, and billing codes for risankizumab (Skyrizi) for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis for Wellmark Blue Cross and Blue Shield - Iowa.All Blue Cross Blue Shield - Iowa updates
- Coverage CriteriaClinical/Medical PolicyEff. 2026-06-03Formulary Medical Necessity ProgramDefines medical necessity criteria and prior-authorization style requirements for non-site-specific outpatient formulary drugs for Blue Cross Blue Shield - Iowa members; applies to medications subject to the Formulary Medical Necessity Program not otherwise managed through drug-specific criteria.All Blue Cross Blue Shield - Iowa updates
- Coverage CriteriaClinical/Medical PolicyEff. 2026-06-03Growth Hormone (somatropin and related products) — Coverage CriteriaCriteria and prior authorization requirements for coverage of growth hormone (somatropin and related products) for pediatric and adult indications under Wellmark (Blue Cross Blue Shield - Iowa). Applies to prescribers and prior authorization reviewers determining medical necessity.All Blue Cross Blue Shield - Iowa updates
- Coverage CriteriaClinical/Medical PolicyEff. 2026-06-03Palynziq (pegvaliase-pqpzl) for phenylketonuria (PKU)Clinical coverage policy for use of Palynziq in adults with phenylketonuria (PKU); describes initial and continuation medical necessity criteria, documentation and prescribing requirements, quantity limits, and dosing guidance for providers and prior authorization reviewers.All Blue Cross Blue Shield - Iowa updates
- Coverage CriteriaClinical/Medical PolicyEff. 2026-06-03Palynziq (pegvaliase-pqpzl) for phenylketonuria (PKU)Coverage criteria and prior authorization requirements for Palynziq (pegvaliase-pqpzl) for treatment of phenylketonuria in members of Wellmark/Blue Cross Blue Shield plans where benefits apply.All Blue Cross Blue Shield - Iowa updates
- Coverage CriteriaClinical/Medical PolicyEff. 2026-06-03Romosozumab (Evenity) for Postmenopausal Osteoporosis — Coverage CriteriaCovers criteria, documentation, and prior authorization requirements for romosozumab (Evenity) in postmenopausal women at high risk for fracture for Wellmark Blue Cross and Blue Shield members.All Blue Cross Blue Shield - Iowa updates
- Coverage CriteriaClinical/Medical PolicyEff. 2026-05-29Cimzia (certolizumab pegol) — prior authorization and coverage criteriaDefines prior authorization, coverage criteria, and documentation requirements for Cimzia (prefilled syringes and lyophilized powder) for Wellmark/Blue Cross Blue Shield members; affects prescribers and pharmacy/medical benefit claim reviewers.All Blue Cross Blue Shield - Iowa updates
- Coverage CriteriaClinical/Medical PolicyEff. 2026-05-29Kineret (anakinra) drug coverageDefines prior authorization, documentation, prescriber specialty, and medical necessity criteria for Kineret (anakinra) for FDA-approved indications and specified compendial uses for Wellmark Blue Cross and Blue Shield members.All Blue Cross Blue Shield - Iowa updates
- Coverage CriteriaClinical/Medical PolicyEff. 2026-05-29Taltz (ixekizumab) — prior authorization and coverage criteriaDefines prior authorization, clinical criteria, and coverage rules for Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis for Wellmark/Blue Cross Blue Shield members.All Blue Cross Blue Shield - Iowa updates
- Coverage CriteriaClinical/Medical PolicyEff. 2026-05-22Disposable Insulin Pumps and Automated Insulin Delivery SystemsThis policy governs prior authorization, coverage criteria, and quantity limits for disposable and tubed insulin pumps and automated insulin delivery (AID) systems (Omnipod family and Twiist) for Wellmark Blue Cross and Blue Shield members.All Blue Cross Blue Shield - Iowa updates
- Coverage CriteriaClinical/Medical PolicyEff. 2026-05-22Intravenous Immune Globulin (IVIG) therapy - Coverage CriteriaThis policy governs medical necessity, prior authorization documentation, and coverage criteria for IVIG products for Wellmark Blue Cross and Blue Shield members; it applies to clinicians prescribing IVIG and to benefit determinations under member contracts.All Blue Cross Blue Shield - Iowa updates
- Coverage CriteriaClinical/Medical PolicyEff. 2026-05-15Aqvesme (mitapivat) and Pyrukynd (mitapivat) — Coverage Criteria for Thalassemia and Pyruvate Kinase DeficiencyPolicy governs prior authorization, coverage criteria, and quantity limits for mitapivat (Aqvesme and Pyrukynd) for treatment of hemolytic anemia due to alpha- or beta-thalassemia and pyruvate kinase (PK) deficiency for Wellmark / Blue Cross Blue Shield members.All Blue Cross Blue Shield - Iowa updates
1–25 of 426
1 / 18
Tool Description
Search Blue Cross Blue Shield - Iowa coverage criteria and medical necessity requirements across 21,000+ policies from 170+ payers.
Search a drug (“Wegovy”), a procedure (“knee replacement”), or a policy name, then filter by payer, specialty, policy type, or effective year. Or start from the largest publishers: UnitedHealthcare coverage criteria and Cigna coverage criteria.
Each result links the full policy page, which lists the clinical requirements, covered codes, and effective dates from the source document.
Pair a criteria search with the prior authorization lookup for approval requirements, the timely filing lookup for claim deadlines, the live policy updates feed for the newest payer publications, and payer profiles for contacts and coverage context.
FAQ
Coverage criteria are the specific clinical requirements a payer sets for covering a drug, procedure, or service: diagnoses, symptom duration, prior treatments tried, age limits, and documentation. They are published inside medical policies and clinical criteria documents, and a claim or authorization that does not meet them is denied as not medically necessary.
Coverage Criteria by Payer
Go deeper
Explore OpenPayer Data
Coverage policies are updated every day. Follow payer coverage policy updates in the live policy feed, or browse all CPT, HCPCS and DRG billing codes.
Toolbox
More OpenPayer Tools
- Billing Code LookupSearch CPT, HCPCS, J-codes, DRG, and dental codes by number or procedure name.
- Billing Code Reimbursement RatesBuild a reimbursement rate report across any mix of billing codes and states, comparing commercial payers against Medicare.
- Payer Comparison DashboardPick 2-5 payers to compare market share, premium, and membership by region, all at once.
- Facility Comparison DashboardPick 2-6 hospital facility types (or add a specific hospital) to compare facility count, revenue, net income, and Medicare/Medicaid payer mix by region, all at once.
- Healthcare Provider & Facility LookupFind hospitals and healthcare facilities by name, taxonomy, facility type, ownership, or state.
- Health Insurance Payer LookupSearch national health insurance payers and health plans by name and state presence.
- Provider Taxonomy Code LookupSearch NUCC taxonomy codes by code, specialty, grouping, or classification.
- CPT Modifier LookupSearch CPT modifiers by code or name — descriptions, when to use them, and payer policy context.
- Prior Authorization LookupSearch payer prior authorization policies by drug, procedure, or policy name.
- Timely Filing LookupFind payer timely filing policies: claim deadlines, corrected claim windows, and appeal timeframes.
- Payer Contact DirectoryClaims, prior authorization, provider services, and appeals contacts for health insurance payers.
Published by
Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.